Abattis Bioceuticals Narrowly Avoids Delisting from Canadian Securities Exchange

Abattis Bioceuticals Corp. (CSE: ATT) appears to have avoided delisting from the Canadian Securities Exchange, if only narrowly. The equity was to be delisted at the close of market this evening as per the CSE bulletin.

Abattis appears to have avoided the delisting event thanks to finally filing its audited financial statements late last night. The firm reported sales of $8,371 for the year ended September 30, 2018, with a net loss of $77.65 million for the full fiscal year.

While avoiding delisting, the Canadian Securities Exchange has listed Abattis as still being suspended for trading, which is likely related to far overdue interim financial statements. Now that the firm has finally filed audited reports for the period ended September 30, 2018, it can focus on filing the first several quarters of fiscal year 2019.

Abattis Bioceuticals for its part indicated that the first and second quarterly financial reports will be filed by the end of next week.


Information for this analysis was found via Sedar, The CSE and Abattis Bioceuticals. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Jay

As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive's stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.

Share
Tweet
WhatsApp
Share
Reddit